Reviews Darbepoetin Alfa


No reviews yet.

Aranesp Drug Description
Aranesp®
(darbepoetin alfa) For Injection

WARNINGS
INCREASED MORTALITY, SERIOUS CARDIOVASCULAR EVENTS, THROMBOEMBOLIC EVENTS, STROKE and INCREASED RISK OF TUMOR PROGRESSION OR RECURRENCE
Chronic Renal Failure:

In clinical studies, patients experienced greater risks for death, serious
cardiovascular events, and stroke when administered erythropoiesis-stimulating
agents (ESAs) to target hemoglobin levels of 13 g/dL and above.
Individualize dosing to achieve and maintain hemoglobin levels within
the range of 10 to 12 g/dL.

Cancer:

ESAs shortened overall survival and/or increased the risk of tumor
progression or recurrence in some clinical studies in patients with breast,
non-small cell lung, head and neck, lymphoid, and cervical cancers (see
WARNINGS: Table 1).
To decrease these risks, as well as the risk of serious cardio- and thrombovascular
events, use the lowest dose needed to avoid red blood cell transfusion.
Because of these risks, prescribers and hospitals must enroll in and
comply with the ESA APPRISE Oncology Program to prescribe and/or dispense
Aranesp® to patients with cancer. To enroll in the ESA APPRISE Oncology
Program, visit www.esa-apprise.com or call 1-866-284-8089 for further assistance.

Use ESAs only for treatment of anemia due to concomitant myelosuppressive
chemotherapy.
ESAs are not indicated for patients receiving myelosuppressive therapy
when the anticipated outcome is cure.
Discontinue following the completion of a chemotherapy course.

(See WARNINGS: Increased Mortality, Serious
Cardiovascular Events, Thromboembolic Events, and Stroke, WARNINGS:
Increased Mortality and/or Increased Risk of Tumor Progression or Recurrence,
INDICATIONS AND USAGE, and DOSAGE
AND ADMINISTRATION.)


DRUG DESCRIPTION



What are the possible side effects of darbepoetin alfa (Aranesp, Aranesp Albumin Free, Aranesp SureClick)?

Contact your doctor if you feel weak, light-headed, or short of breath, or if your skin looks pale. These may be signs that your body has stopped responding to darbepoetin alfa.
Darbepoetin alfa can increase your risk of life-threatening heart or circulation problems, including heart attack or stroke. This risk will increase the longer you use darbepoetin alfa. Seek emergency medical help if you have symptoms of heart or circulation problems, such as:

...
Read All Potential Side Effects for Aranesp »




Aranesp® is an erythropoiesis stimulating protein, closely related to erythropoietin,
that is produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.
Aranesp® is a 165-amino acid protein that differs from recombinant human
erythropoietin in containing 5 N-linked oligosaccharide chains, whereas recombinant
human erythropoietin contains 3 chains.1 The two additional N-glycosylation
sites result from amino acid substitutions in the erythropoietin peptide backbone.
The additional carbohydrate chains increase the approximate molecular weight
of the glycoprotein from 30,000 to 37,000 daltons. Aranesp® is formulated
as a sterile, colorless, preservative-free protein solution for intravenous
or subcutaneous administration.
Single-dose vials are available containing 25, 40, 60, 100, 150, 200,
300, or 500 mcg of Aranesp®.
Single-dose prefilled syringes and prefilled SureClick™ autoinjectors
are available containing 25, 40, 60, 100, 150, 200, 300, or 500 mcg of Aranesp®.
Each prefilled syringe is equipped with a needle guard that covers the needle
during disposal.
Single-dose vials, prefilled syringes and autoinjectors are available in two
formulations that contain excipients as follows:

Polysorbate solution Each 1 mL contains 0.05 mg polysorbate 80, and
is formulated at pH 6.2 ± 0.2 with 2.12 mg sodium phosphate monobasic
monohydrate, 0.66 mg sodium phosphate dibasic anhydrous, and 8.18 mg sodium
chloride in Water for Injection, USP (to 1 mL).
Albumin solution Each 1 mL contains 2.5 mg albumin (human), and is
formulated at pH 6.0 ± 0.3 with 2.23 mg sodium phosphate monobasic
monohydrate, 0.53 mg sodium phosphate dibasic anhydrous, and 8.18 mg sodium
chloride in Water for Injection, USP (to 1 mL).

1. Egrie JC, Browne JK. Development and characterization of
novel erythropoiesis stimulating protein (NESP). Br J Cancer. 2001; 84 (suppl
1): 3-10.
Last reviewed on RxList: 2/25/2010




Aranesp Drug Description
Aranesp®
(darbepoetin alfa) For Injection

WARNINGS
INCREASED MORTALITY, SERIOUS CARDIOVASCULAR EVENTS, THROMBOEMBOLIC EVENTS, STROKE and INCREASED RISK OF TUMOR PROGRESSION OR RECURRENCE
Chronic Renal Failure:

In clinical studies, patients experienced greater risks for death, serious
cardiovascular events, and stroke when administered erythropoiesis-stimulating
agents (ESAs) to target hemoglobin levels of 13 g/dL and above.
Individualize dosing to achieve and maintain hemoglobin levels within
the range of 10 to 12 g/dL.

Cancer:

ESAs shortened overall survival and/or increased the risk of tumor
progression or recurrence in some clinical studies in patients with breast,
non-small cell lung, head and neck, lymphoid, and cervical cancers (see
WARNINGS: Table 1).
To decrease these risks, as well as the risk of serious cardio- and thrombovascular
events, use the lowest dose needed to avoid red blood cell transfusion.
Because of these risks, prescribers and hospitals must enroll in and
comply with the ESA APPRISE Oncology Program to prescribe and/or dispense
Aranesp® to patients with cancer. To enroll in the ESA APPRISE Oncology
Program, visit www.esa-apprise.com or call 1-866-284-8089 for further assistance.

Use ESAs only for treatment of anemia due to concomitant myelosuppressive
chemotherapy.
ESAs are not indicated for patients receiving myelosuppressive therapy
when the anticipated outcome is cure.
Discontinue following the completion of a chemotherapy course.

(See WARNINGS: Increased Mortality, Serious
Cardiovascular Events, Thromboembolic Events, and Stroke, WARNINGS:
Increased Mortality and/or Increased Risk of Tumor Progression or Recurrence,
INDICATIONS AND USAGE, and DOSAGE
AND ADMINISTRATION.)


DRUG DESCRIPTION



What are the possible side effects of darbepoetin alfa (Aranesp, Aranesp Albumin Free, Aranesp SureClick)?

Contact your doctor if you feel weak, light-headed, or short of breath, or if your skin looks pale. These may be signs that your body has stopped responding to darbepoetin alfa.
Darbepoetin alfa can increase your risk of life-threatening heart or circulation problems, including heart attack or stroke. This risk will increase the longer you use darbepoetin alfa. Seek emergency medical help if you have symptoms of heart or circulation problems, such as:

...
Read All Potential Side Effects for Aranesp »




Aranesp® is an erythropoiesis stimulating protein, closely related to erythropoietin,
that is produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.
Aranesp® is a 165-amino acid protein that differs from recombinant human
erythropoietin in containing 5 N-linked oligosaccharide chains, whereas recombinant
human erythropoietin contains 3 chains.1 The two additional N-glycosylation
sites result from amino acid substitutions in the erythropoietin peptide backbone.
The additional carbohydrate chains increase the approximate molecular weight
of the glycoprotein from 30,000 to 37,000 daltons. Aranesp® is formulated
as a sterile, colorless, preservative-free protein solution for intravenous
or subcutaneous administration.
Single-dose vials are available containing 25, 40, 60, 100, 150, 200,
300, or 500 mcg of Aranesp®.
Single-dose prefilled syringes and prefilled SureClick™ autoinjectors
are available containing 25, 40, 60, 100, 150, 200, 300, or 500 mcg of Aranesp®.
Each prefilled syringe is equipped with a needle guard that covers the needle
during disposal.
Single-dose vials, prefilled syringes and autoinjectors are available in two
formulations that contain excipients as follows:

Polysorbate solution Each 1 mL contains 0.05 mg polysorbate 80, and
is formulated at pH 6.2 ± 0.2 with 2.12 mg sodium phosphate monobasic
monohydrate, 0.66 mg sodium phosphate dibasic anhydrous, and 8.18 mg sodium
chloride in Water for Injection, USP (to 1 mL).
Albumin solution Each 1 mL contains 2.5 mg albumin (human), and is
formulated at pH 6.0 ± 0.3 with 2.23 mg sodium phosphate monobasic
monohydrate, 0.53 mg sodium phosphate dibasic anhydrous, and 8.18 mg sodium
chloride in Water for Injection, USP (to 1 mL).

1. Egrie JC, Browne JK. Development and characterization of
novel erythropoiesis stimulating protein (NESP). Br J Cancer. 2001; 84 (suppl
1): 3-10.
Last reviewed on RxList: 2/25/2010




Aranesp Drug Description
Aranesp®
(darbepoetin alfa) For Injection

WARNINGS
INCREASED MORTALITY, SERIOUS CARDIOVASCULAR EVENTS, THROMBOEMBOLIC EVENTS, STROKE and INCREASED RISK OF TUMOR PROGRESSION OR RECURRENCE
Chronic Renal Failure:

In clinical studies, patients experienced greater risks for death, serious
cardiovascular events, and stroke when administered erythropoiesis-stimulating
agents (ESAs) to target hemoglobin levels of 13 g/dL and above.
Individualize dosing to achieve and maintain hemoglobin levels within
the range of 10 to 12 g/dL.

Cancer:

ESAs shortened overall survival and/or increased the risk of tumor
progression or recurrence in some clinical studies in patients with breast,
non-small cell lung, head and neck, lymphoid, and cervical cancers (see
WARNINGS: Table 1).
To decrease these risks, as well as the risk of serious cardio- and thrombovascular
events, use the lowest dose needed to avoid red blood cell transfusion.
Because of these risks, prescribers and hospitals must enroll in and
comply with the ESA APPRISE Oncology Program to prescribe and/or dispense
Aranesp® to patients with cancer. To enroll in the ESA APPRISE Oncology
Program, visit www.esa-apprise.com or call 1-866-284-8089 for further assistance.

Use ESAs only for treatment of anemia due to concomitant myelosuppressive
chemotherapy.
ESAs are not indicated for patients receiving myelosuppressive therapy
when the anticipated outcome is cure.
Discontinue following the completion of a chemotherapy course.

(See WARNINGS: Increased Mortality, Serious
Cardiovascular Events, Thromboembolic Events, and Stroke, WARNINGS:
Increased Mortality and/or Increased Risk of Tumor Progression or Recurrence,
INDICATIONS AND USAGE, and DOSAGE
AND ADMINISTRATION.)


DRUG DESCRIPTION



What are the possible side effects of darbepoetin alfa (Aranesp, Aranesp Albumin Free, Aranesp SureClick)?

Contact your doctor if you feel weak, light-headed, or short of breath, or if your skin looks pale. These may be signs that your body has stopped responding to darbepoetin alfa.
Darbepoetin alfa can increase your risk of life-threatening heart or circulation problems, including heart attack or stroke. This risk will increase the longer you use darbepoetin alfa. Seek emergency medical help if you have symptoms of heart or circulation problems, such as:

...
Read All Potential Side Effects for Aranesp »




Aranesp® is an erythropoiesis stimulating protein, closely related to erythropoietin,
that is produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.
Aranesp® is a 165-amino acid protein that differs from recombinant human
erythropoietin in containing 5 N-linked oligosaccharide chains, whereas recombinant
human erythropoietin contains 3 chains.1 The two additional N-glycosylation
sites result from amino acid substitutions in the erythropoietin peptide backbone.
The additional carbohydrate chains increase the approximate molecular weight
of the glycoprotein from 30,000 to 37,000 daltons. Aranesp® is formulated
as a sterile, colorless, preservative-free protein solution for intravenous
or subcutaneous administration.
Single-dose vials are available containing 25, 40, 60, 100, 150, 200,
300, or 500 mcg of Aranesp®.
Single-dose prefilled syringes and prefilled SureClick™ autoinjectors
are available containing 25, 40, 60, 100, 150, 200, 300, or 500 mcg of Aranesp®.
Each prefilled syringe is equipped with a needle guard that covers the needle
during disposal.
Single-dose vials, prefilled syringes and autoinjectors are available in two
formulations that contain excipients as follows:

Polysorbate solution Each 1 mL contains 0.05 mg polysorbate 80, and
is formulated at pH 6.2 ± 0.2 with 2.12 mg sodium phosphate monobasic
monohydrate, 0.66 mg sodium phosphate dibasic anhydrous, and 8.18 mg sodium
chloride in Water for Injection, USP (to 1 mL).
Albumin solution Each 1 mL contains 2.5 mg albumin (human), and is
formulated at pH 6.0 ± 0.3 with 2.23 mg sodium phosphate monobasic
monohydrate, 0.53 mg sodium phosphate dibasic anhydrous, and 8.18 mg sodium
chloride in Water for Injection, USP (to 1 mL).

1. Egrie JC, Browne JK. Development and characterization of
novel erythropoiesis stimulating protein (NESP). Br J Cancer. 2001; 84 (suppl
1): 3-10.
Last reviewed on RxList: 2/25/2010




Aranesp Drug Description
Aranesp®
(darbepoetin alfa) For Injection

WARNINGS
INCREASED MORTALITY, SERIOUS CARDIOVASCULAR EVENTS, THROMBOEMBOLIC EVENTS, STROKE and INCREASED RISK OF TUMOR PROGRESSION OR RECURRENCE
Chronic Renal Failure:

In clinical studies, patients experienced greater risks for death, serious
cardiovascular events, and stroke when administered erythropoiesis-stimulating
agents (ESAs) to target hemoglobin levels of 13 g/dL and above.
Individualize dosing to achieve and maintain hemoglobin levels within
the range of 10 to 12 g/dL.

Cancer:

ESAs shortened overall survival and/or increased the risk of tumor
progression or recurrence in some clinical studies in patients with breast,
non-small cell lung, head and neck, lymphoid, and cervical cancers (see
WARNINGS: Table 1).
To decrease these risks, as well as the risk of serious cardio- and thrombovascular
events, use the lowest dose needed to avoid red blood cell transfusion.
Because of these risks, prescribers and hospitals must enroll in and
comply with the ESA APPRISE Oncology Program to prescribe and/or dispense
Aranesp® to patients with cancer. To enroll in the ESA APPRISE Oncology
Program, visit www.esa-apprise.com or call 1-866-284-8089 for further assistance.

Use ESAs only for treatment of anemia due to concomitant myelosuppressive
chemotherapy.
ESAs are not indicated for patients receiving myelosuppressive therapy
when the anticipated outcome is cure.
Discontinue following the completion of a chemotherapy course.

(See WARNINGS: Increased Mortality, Serious
Cardiovascular Events, Thromboembolic Events, and Stroke, WARNINGS:
Increased Mortality and/or Increased Risk of Tumor Progression or Recurrence,
INDICATIONS AND USAGE, and DOSAGE
AND ADMINISTRATION.)


DRUG DESCRIPTION



What are the possible side effects of darbepoetin alfa (Aranesp, Aranesp Albumin Free, Aranesp SureClick)?

Contact your doctor if you feel weak, light-headed, or short of breath, or if your skin looks pale. These may be signs that your body has stopped responding to darbepoetin alfa.
Darbepoetin alfa can increase your risk of life-threatening heart or circulation problems, including heart attack or stroke. This risk will increase the longer you use darbepoetin alfa. Seek emergency medical help if you have symptoms of heart or circulation problems, such as:

...
Read All Potential Side Effects for Aranesp »




Aranesp® is an erythropoiesis stimulating protein, closely related to erythropoietin,
that is produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.
Aranesp® is a 165-amino acid protein that differs from recombinant human
erythropoietin in containing 5 N-linked oligosaccharide chains, whereas recombinant
human erythropoietin contains 3 chains.1 The two additional N-glycosylation
sites result from amino acid substitutions in the erythropoietin peptide backbone.
The additional carbohydrate chains increase the approximate molecular weight
of the glycoprotein from 30,000 to 37,000 daltons. Aranesp® is formulated
as a sterile, colorless, preservative-free protein solution for intravenous
or subcutaneous administration.
Single-dose vials are available containing 25, 40, 60, 100, 150, 200,
300, or 500 mcg of Aranesp®.
Single-dose prefilled syringes and prefilled SureClick™ autoinjectors
are available containing 25, 40, 60, 100, 150, 200, 300, or 500 mcg of Aranesp®.
Each prefilled syringe is equipped with a needle guard that covers the needle
during disposal.
Single-dose vials, prefilled syringes and autoinjectors are available in two
formulations that contain excipients as follows:

Polysorbate solution Each 1 mL contains 0.05 mg polysorbate 80, and
is formulated at pH 6.2 ± 0.2 with 2.12 mg sodium phosphate monobasic
monohydrate, 0.66 mg sodium phosphate dibasic anhydrous, and 8.18 mg sodium
chloride in Water for Injection, USP (to 1 mL).
Albumin solution Each 1 mL contains 2.5 mg albumin (human), and is
formulated at pH 6.0 ± 0.3 with 2.23 mg sodium phosphate monobasic
monohydrate, 0.53 mg sodium phosphate dibasic anhydrous, and 8.18 mg sodium
chloride in Water for Injection, USP (to 1 mL).

1. Egrie JC, Browne JK. Development and characterization of
novel erythropoiesis stimulating protein (NESP). Br J Cancer. 2001; 84 (suppl
1): 3-10.
Last reviewed on RxList: 2/25/2010




Aranesp Drug Description
Aranesp®
(darbepoetin alfa) For Injection

WARNINGS
INCREASED MORTALITY, SERIOUS CARDIOVASCULAR EVENTS, THROMBOEMBOLIC EVENTS, STROKE and INCREASED RISK OF TUMOR PROGRESSION OR RECURRENCE
Chronic Renal Failure:

In clinical studies, patients experienced greater risks for death, serious
cardiovascular events, and stroke when administered erythropoiesis-stimulating
agents (ESAs) to target hemoglobin levels of 13 g/dL and above.
Individualize dosing to achieve and maintain hemoglobin levels within
the range of 10 to 12 g/dL.

Cancer:

ESAs shortened overall survival and/or increased the risk of tumor
progression or recurrence in some clinical studies in patients with breast,
non-small cell lung, head and neck, lymphoid, and cervical cancers (see
WARNINGS: Table 1).
To decrease these risks, as well as the risk of serious cardio- and thrombovascular
events, use the lowest dose needed to avoid red blood cell transfusion.
Because of these risks, prescribers and hospitals must enroll in and
comply with the ESA APPRISE Oncology Program to prescribe and/or dispense
Aranesp® to patients with cancer. To enroll in the ESA APPRISE Oncology
Program, visit www.esa-apprise.com or call 1-866-284-8089 for further assistance.

Use ESAs only for treatment of anemia due to concomitant myelosuppressive
chemotherapy.
ESAs are not indicated for patients receiving myelosuppressive therapy
when the anticipated outcome is cure.
Discontinue following the completion of a chemotherapy course.

(See WARNINGS: Increased Mortality, Serious
Cardiovascular Events, Thromboembolic Events, and Stroke, WARNINGS:
Increased Mortality and/or Increased Risk of Tumor Progression or Recurrence,
INDICATIONS AND USAGE, and DOSAGE
AND ADMINISTRATION.)


DRUG DESCRIPTION



What are the possible side effects of darbepoetin alfa (Aranesp, Aranesp Albumin Free, Aranesp SureClick)?

Contact your doctor if you feel weak, light-headed, or short of breath, or if your skin looks pale. These may be signs that your body has stopped responding to darbepoetin alfa.
Darbepoetin alfa can increase your risk of life-threatening heart or circulation problems, including heart attack or stroke. This risk will increase the longer you use darbepoetin alfa. Seek emergency medical help if you have symptoms of heart or circulation problems, such as:

...
Read All Potential Side Effects for Aranesp »




Aranesp® is an erythropoiesis stimulating protein, closely related to erythropoietin,
that is produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.
Aranesp® is a 165-amino acid protein that differs from recombinant human
erythropoietin in containing 5 N-linked oligosaccharide chains, whereas recombinant
human erythropoietin contains 3 chains.1 The two additional N-glycosylation
sites result from amino acid substitutions in the erythropoietin peptide backbone.
The additional carbohydrate chains increase the approximate molecular weight
of the glycoprotein from 30,000 to 37,000 daltons. Aranesp® is formulated
as a sterile, colorless, preservative-free protein solution for intravenous
or subcutaneous administration.
Single-dose vials are available containing 25, 40, 60, 100, 150, 200,
300, or 500 mcg of Aranesp®.
Single-dose prefilled syringes and prefilled SureClick™ autoinjectors
are available containing 25, 40, 60, 100, 150, 200, 300, or 500 mcg of Aranesp®.
Each prefilled syringe is equipped with a needle guard that covers the needle
during disposal.
Single-dose vials, prefilled syringes and autoinjectors are available in two
formulations that contain excipients as follows:

Polysorbate solution Each 1 mL contains 0.05 mg polysorbate 80, and
is formulated at pH 6.2 ± 0.2 with 2.12 mg sodium phosphate monobasic
monohydrate, 0.66 mg sodium phosphate dibasic anhydrous, and 8.18 mg sodium
chloride in Water for Injection, USP (to 1 mL).
Albumin solution Each 1 mL contains 2.5 mg albumin (human), and is
formulated at pH 6.0 ± 0.3 with 2.23 mg sodium phosphate monobasic
monohydrate, 0.53 mg sodium phosphate dibasic anhydrous, and 8.18 mg sodium
chloride in Water for Injection, USP (to 1 mL).

1. Egrie JC, Browne JK. Development and characterization of
novel erythropoiesis stimulating protein (NESP). Br J Cancer. 2001; 84 (suppl
1): 3-10.
Last reviewed on RxList: 2/25/2010





Other reviews about Darbepoetin Alfa on wordpress

Erythropoiesis Stimulating Agents: Aranesp (darbepoetin alfa), Epogen (epoetin alfa), and Procrit (epoetin alfa)
  by Law Offices of Sadaka Associates
FDA informed healthcare professionals of findings from two additional clinical studies, Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE), and the National Cancer Institute Gynecologic Oncology Group (COG-19), showing an […]


Increased Worldwide Focus on the Safety of Drugs Used To Treat Chemotherapy-Related Anemia
  by Libby's H*O*P*E*
Over the past month, there was considerable press coverage regarding the safety and proper use of epoetin alfa (marketed as Epogen® & Procrit®) and darbepoetin (marketed as Aranesp®). […]


McFadden's suspended 10 years - DPO found
  by Shedrow Queen
Wow! Now this is the kind of penalty that sends a message! Harnesslink Admin 01:47 AM 20-Dec-2008 As a result of an investigation by the industry-funded Equine Medication Control […]


Halloween trick: don't TREAT diabetes with ESAs
  by Larry Husten
In the first adequately powered trial of an erythropoiesis-stimulating agent (ESA), darbepoetin alfa (Aranesp, Amgen) failed to reduce major clinical events and was associated with an increased risk […]


Considerable stroke risk linked to anemia drug; Darbepoetin-α [Aranesp] nearly doubled risk in people with diabetes
  by thassodotcom
November 1, 2009 - A new study raises fresh safety concerns about widely used anemia medicines, finding that the drug Darbepoetin-α [Aranesp] nearly doubled the risk of stroke […]


Agentes estimulantes da Eritropoese - tempo para uma reavaliação
  by Edmilson Lima
Erythropoiesis-Stimulating Agents — Time for a Reevaluation Ellis F. Unger, M.D., Aliza M. Thompson, M.D., Melanie J. Blank, M.D., and Robert Temple, M.D.  New England Journal of […]


Doping - How far will you go?
  by corcoranstrength
With the recent news about the Waterloo football team, my question to any athlete out there is "how far will you go to win?" Here is an article looking […]


Avoiding That "Next Iceberg" -- Of "Negative" Studies
  by condor
A gracious anonymous commenter points us to this well-thought out Wa Po item -- do go read it all, and keep the ENHANCE study, the SEAS study […]


Dr Reddy's launches biosimilar drug for anaemia treatment
  by INDOLINK Consulting (es)
Source: The Hindu Business Line, Aug 10, 2010 Hyderabad: Dr Reddy's Laboratories Ltd has launched Cresp, the first generic darbepoetin alfa drug in the world for the treatment of anaemia […]


TREAT Analysis: Target Dosing is Tricky
  by Larry Husten
A new analysis of TREAT (Trial to Reduce Cardiovascular Events with Aranesp Therapy) is raising questions about the use of target-based strategies for the treatment of anemia in […]



Other reviews about Darbepoetin Alfa on web:

Darbepoetin alfa (pronounced /dɑrbəˈpɔɪtɨn/) is a synthetic form of erythropoietin. It stimulates erythropoiesis (increases red blood cell levels) and is used to treat anemia ... Darbepoetin alfa - Wikipedia, the free encyclopedia


Manufacturer provides indications, side effects, contraindications and mechanisms of action of this treatment for anemia associated with chronic renal failure and chemotherapy. Aranesp®(darbepoetin alfa)


Consumer information about the medication DARBEPOETIN ALFA - INJECTABLE (Aranesp), includes side effects, drug interactions, recommended dosages, and storage information. Read ... DARBEPOETIN ALFA - INJECTABLE (Aranesp) side effects, medical uses ...


Darbepoetin Alfa Brand names: Aranesp® Español: Darbepoetina Alfa Solución para inyección Darbepoetin Alfa Solution for injection What is this Darbepoetin alfa: Information from Answers.com


Learn about the prescription medication Aranesp (Darbepoetin Alfa), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Aranesp (Darbepoetin Alfa) Drug Information: Uses, Side Effects ...


Physician reviewed darbepoetin alfa patient information - includes darbepoetin alfa description, dosage and directions. darbepoetin alfa medical facts from Drugs.com


Darbepoetin alfa is a biologic response modifier. It is an erythropoiesis stimulating protein. Aranesp Darbepoietin Alfa, Aranesp - Chemotherapy Drugs, Chemo Drug Side ...


All patients: Darbepoetin alfa injection increases the risk of blood clots forming in or moving to the legs, lungs, or brain. Call your doctor immediately if you experience any of ... Darbepoetin Alfa Injection: MedlinePlus Drug Information


Darbepoetin Alfa professional patient advice. Specific and up to date information about Darbepoetin Alfa. Complete Darbepoetin Alfa information from Drugs.com


Get information on how Darbepoetin Alfa Injection is used, including different forms of the medication and how they should be taken. Learn about Darbepoetin Alfa Injection from Consumer Reports Health.





Featured Reviews

Reviews Nilandron

Nilandron Drug Description NILANDRON® (nilutamide) Tablets DRUG DESCRIPTION What are the possible side effects of nilutamide (Nilandron)? If you experience any of the following serious side effects, stop taking nilutamide,...
Read More  |  Review This
Reviews Droperidol

Inapsine Drug Description INAPSINE® (droperidol) Injection For intravenous or intramuscular use only WARNING Cases of QT prolongation and/or torsade de pointes have been reported in patients receiving Inapsine at doses at or...
Read More  |  Review This
Reviews Alphagan-P

Alphagan-P Drug Description ALPHAGAN® P (brimonidine tartrate) Ophthalmic Solution 0.1% and 0.15% Sterile DRUG DESCRIPTION What are the possible side effects of brimonidine ophthalmic (Alphagan P)? Stop using brimonidine and...
Read More  |  Review This
Reviews Hydrocortisone Sodium Succinate

Solu Cortef Drug Description SOLU-CORTEF® (hydrocortisone sodium succinate) for Injection, USP For Intravenous or Intramuscular Administration DRUG DESCRIPTION SOLU-CORTEF Sterile Powder is an anti-inflammatory glucocorticoid, which...
Read More  |  Review This
Reviews Menostar

Menostar Drug Description Menostar® (estradiol) Transdermal System ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER Close clinical surveillance of all women taking estrogens is important. Adequate diagnostic measures,...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....